Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181393 | 0.80 | HDAC1 (0.41) | HDAC1HDAC2HDAC8HDAC6CTSB | |
| SCHEMBL5320356 | 0.79 | LTA4H (0.59) | LTA4H | |
| SCHEMBL5678125 | 0.77 | LTA4H (0.57) | LTA4HCTSBCTSSKMT2A | |
| Hydrochloric Acid SCHEMBL6008696 | 0.77 | LTA4H (0.57) | LTA4H | |
| SCHEMBL9894470 | 0.76 | HDAC3 (0.57) | HDAC1HDAC2HDAC8HDAC6LTA4H | |
| SCHEMBL9894467 | 0.76 | HDAC3 (0.57) | HDAC1HDAC2HDAC8HDAC6LTA4H | |
| SCHEMBL7896997 | 0.74 | LTA4H (0.46) | HDAC1HDAC2HDAC8HDAC6LTA4H | |
| SCHEMBL1837653 | 0.72 | CTSB (0.67) | HDAC1HDAC2HDAC8HDAC6CTSB | |
| SCHEMBL10458177 | 0.72 | LTA4H (0.51) | LTA4HMEN1KMT2A | |
| SCHEMBL16112075 | 0.71 | LTA4H (0.44) | LTA4HCTSBCTSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | claimed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | claimed |
| EP-2401257-A1 | ENZYME INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | claimed |
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| CN-101959534-B | Enzyme and receptor modulation | CHROMA THERAPEUTICS LTD | 2013-11-27 | — | — | CN | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| CN-101959534-A | Enzyme and receptor modulation | CHROMA THERAPEUTICS LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| EP-2252328-A2 | INTRACELLULAR ENZYME AND RECEPTOR MODULATION | Chroma Therapeutics Ltd. (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009106848-A2 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106848-A2 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | HDAC1 1/4885HDAC2 6/4885HDAC8 13/4885 |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC1 2824/4885HDAC2 3371/4885HDAC8 2282/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 4/4885HDAC8 11/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC1 2824/4885HDAC2 3371/4885HDAC8 2282/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | HDAC1 2/4885HDAC2 9/4885HDAC8 10/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC1 2824/4885HDAC2 3371/4885HDAC8 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.